Meeting
2020 ASCO Virtual Scientific Program
Phase II study of nivolumab and ipilimumab for advanced rare genitourinary cancers.
Authors
Bradley Alexander McGregor
Dana-Farber Cancer Institute, Boston, MA
Bradley Alexander McGregor , Matthew T Campbell , Wanling Xie , Subrina Farah , Mehmet Asim Bilen , Guru Sonpavde , Kerry L. Kilbridge , Atish Dipankar Choudhury , Amir Mortazavi , Amishi Yogesh Shah , Aradhana M. Venkatesan , Glenn Bubley , Arlene O. Siefker-Radtke , Rana R. McKay , Toni K. Choueiri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Bladder Cancer
Clinical Trial Registration Number
NCT 03333616
Citation
J Clin Oncol 38: 2020 (suppl; abstr 5018)
DOI
10.1200/JCO.2020.38.15_suppl.5018
Abstract #
5018
Poster Bd #
87
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with variant histologies (RCCvh).
First Author: Bradley Alexander McGregor
Poster
2021 ASCO Annual Meeting
Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced non-clear cell renal cell carcinoma (nccRCC) (HCRN GU16-260-Cohort B).
First Author: Michael B. Atkins
Poster
2019 ASCO Annual Meeting
Phase II study of nivolumab and ipilimumab for advanced bladder cancer of variant histologies (BCVH).
First Author: Bradley Alexander McGregor
Poster
2024 ASCO Annual Meeting
Seven year update on SOC-1702: A phase 2 study using trabectedin (T) in combination with ipilimumab (I), nivolumab (N) and trabectedin (T) in previously untreated patients with advanced soft tissue sarcoma.
First Author: Erlinda Maria Gordon